S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NYSE:ADCT

ADC Therapeutics (ADCT) Stock Forecast, Price & News

$0.81
+0.09 (+12.53%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.68
$0.81
50-Day Range
$0.72
$1.68
52-Week Range
$0.68
$5.75
Volume
345,515 shs
Average Volume
518,466 shs
Market Capitalization
$62.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20

ADC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
914.2% Upside
$8.20 Price Target
Short Interest
Bearish
8.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of ADC Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.41) to ($2.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

442nd out of 963 stocks

Pharmaceutical Preparations Industry

188th out of 444 stocks


ADCT stock logo

About ADC Therapeutics (NYSE:ADCT) Stock

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Price History

ADCT Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Q2 2023 ADC Therapeutics SA Earnings Call
A Preview Of ADC Therapeutics's Earnings
MannKind (MNKD) Reports Break-Even Earnings for Q2
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADCT Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
317
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.20
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+914.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-155,800,000.00
Pretax Margin
-100.29%

Debt

Sales & Book Value

Annual Sales
$184.39 million
Book Value
$1.16 per share

Miscellaneous

Free Float
49,619,000
Market Cap
$62.10 million
Optionable
Not Optionable
Beta
1.01
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 50)
    M.S., CEO & Director
    Comp: $830.03k
  • Mr. Jose I. Carmona M.B.A. (Age 51)
    Chief Financial Officer
  • Dr. Patrick van Berkel Ph.D. (Age 55)
    Chief Scientific Officer
  • Dr. Michael Mulkerrin Ph.D. (Age 68)
    Chief Technical Operations Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Ms. Susan Romanus (Age 58)
    Chief Compliance & Quality Officer
  • Mr. Peter J. Graham Esq. (Age 56)
    Chief Legal Officer
  • Ms. Kimberly Pope (Age 56)
    Sr. VP & Chief People Officer
  • Mr. David M. Gilman (Age 50)
    Chief Bus. & Strategy Officer
  • Ms. Kristen Harrington-Smith (Age 50)
    Chief Commercial Officer













ADCT Stock - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price forecast for 2023?

6 brokerages have issued 1-year price objectives for ADC Therapeutics' stock. Their ADCT share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $8.20 in the next year. This suggests a possible upside of 914.2% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2023?

ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT stock has decreased by 78.9% and is now trading at $0.8085.
View the best growth stocks for 2023 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a decline in short interest in August. As of August 15th, there was short interest totaling 5,320,000 shares, a decline of 13.6% from the July 31st total of 6,160,000 shares. Based on an average daily volume of 461,400 shares, the days-to-cover ratio is presently 11.5 days. Currently, 8.5% of the shares of the stock are sold short.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, August, 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.14. The business earned $19.28 million during the quarter, compared to analyst estimates of $34.77 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 325.79% and a negative net margin of 98.33%.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

What is ADC Therapeutics' stock symbol?

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (7.27%), JPMorgan Chase & Co. (3.59%), Goldman Sachs Group Inc. (1.48%), Vantage Consulting Group Inc (1.15%), AlphaCentric Advisors LLC (1.01%) and BlackRock Inc. (0.61%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADC Therapeutics' stock price today?

One share of ADCT stock can currently be purchased for approximately $0.81.

How much money does ADC Therapeutics make?

ADC Therapeutics (NYSE:ADCT) has a market capitalization of $62.10 million and generates $184.39 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does ADC Therapeutics have?

The company employs 317 workers across the globe.

How can I contact ADC Therapeutics?

The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com.

This page (NYSE:ADCT) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -